magrolimab + zimberelimab + 5-fluorouracil + platinum chemotherapy

A four-drug combination therapy comprised of magrolimab, zimberelimab, 5-fluorouracil, and a platinum-based chemotherapy. - **Magrolimab** is a humanized monoclonal antibody targeting CD47, a “do not eat me” signal overexpressed on many cancer cells; it blocks the CD47–SIRPα interaction, facilitating phagocytosis of tumor cells by macrophages and enhancing innate and adaptive antitumor immune responses[1][5]. - **Zimberelimab** is a monoclonal antibody that targets programmed death-1 (PD-1), acting as a checkpoint inhibitor to potentiate T-cell-mediated immune responses against tumors. - **5-Fluorouracil** is an antimetabolite (pyrimidine analog) that inhibits DNA synthesis, widely used as a cytotoxic chemotherapeutic. - **Platinum chemotherapy** refers to DNA-crosslinking agents (such as cisplatin, carboplatin, or oxaliplatin) that induce apoptosis in rapidly dividing cells by forming DNA adducts. This combination is being explored primarily as an oncology regimen for solid tumors, leveraging both immunotherapy (magrolimab and zimberelimab) and cytotoxic chemotherapy (5-fluorouracil and platinum compounds).